Clinical trial NCT04717336: Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)
Official title: Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study(GENE-FORECAST): Sodium Intervention Trial (SIT)/GENE-FORECAST SIT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Disease
Keywords: African American
Cardiovascular Disease
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
Collaborators: name: National Human Genome Research Institute (NHGRI)
First posted: 2021-01-22
Enrollment: 36
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Background:

Hypertension is a risk factor for heart disease. Low-sodium diets rich in fruits, vegetables, and other healthy foods are a good way to reduce blood pressure in people with hypertension. Researchers want to learn more about why African Americans seem to have the greatest benefit from certain dietary interventions.

Objective:

To better understand the body's response to adding more salt to the diet.

Eligibility:

U.S.-born African American adults ages 21 to 65 who are in good general health and took part in the GENE-FORECAST.

Design:

Participants will be screened with a medical history and physical exam. If needed, they will take a pregnancy test. These tests will be repeated during the study.

Each day for 2 weeks, participants will take 3 capsules that contain either placebo or salt. Then they will take no pills for 3 weeks. Then they will take placebo or salt capsules for 2 more weeks.

Participants will talk about the foods and drinks they have consumed over the past 24 hours. They will take a survey about their physical activity and sleep.

Participants will complete taste tasks to obtain their responses to sweetness or saltiness. Sucrose and salt detection thresholds and preferences will be assessed.

Participants will give blood and urine samples. Saliva samples will be collected from their mouth by passive drool or by spitting into a sterile tube. Skin samples will be collected from behind their ears and the inner part of their elbow, using sterile swabs. Participants will get kits to collect stool samples at home.

Participants will have 4 study visits over 7 weeks.

Detailed description: The objective of this study is to implement a sodium intervention investigation to assess the effect of increased dietary sodium intake on changes in blood pressure, vascular function, microbiome, whole blood epigenome, whole blood and urine transcriptome as outcome measures. The study design will include a double-blind, cross-over treatment/placebo trial among African Americans GENE-FORECAST participants with normal blood pressure and will last 7 weeks. It is hypothesized that exposure to increased dietary sodium will affect blood pressure, whole blood epigenome, whole blood and urine transcriptome, vascular function, microbiome and blood pressure.

Eligibility criteria: * INCLUSION CRITERIA:

African American men and women who are former GENE-FORECAST participants between 21 and 65 years of age. This criterion is inclusive of self-identified AA of both Hispanic, Latino and non-Hispanic, Latino ethnicities. Normotensive participants with systolic blood pressure (SBP) \<140 mm Hg and diastolic blood pressure (DBP) \<90 mm Hg and the absence of a history of prior diagnosis of hypertension.

-Willingness and ability to participate in study procedures.

EXCLUSION CRITERIA:

* Individuals who are pregnant or breast-feeding.
* Individuals with high blood pressure or a history of hypertension.
* Individuals with a history of myocardial infarction, stroke, heart failure, diabetes, chronic liver or kidney diseases.
* Individuals who are taking antihypertensive, antidepressants, antidiabetic and antibiotic medications.
* Individuals currently participating in another NIH protocol.
* Individuals unable to provide informed consent.

Primary outcomes:
measure: Mean Change in Vascular Function Measured by Pulse Wave Velocity
timeFrame: Baseline, Week 2, Week 5 and Week 7
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Institutes of Health Clinical Center
state: Maryland
Study officials:
affiliation: National Human Genome Research Institute (NHGRI)
name: Amadou Gaye, PhD
role: PRINCIPAL_INVESTIGATOR
References: